Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15956017 | 0.89 | KDM4E (0.37) | KDM4ETDP1ENPP2MMP3 | |
| SCHEMBL4007007 | 0.86 | KDM4E (0.52) | KDM4ETDP1ENPP2MEN1KMT2A | |
| SCHEMBL641274 | 0.84 | KDM4E (0.37) | KDM4ETDP1ENPP2MMP3 | |
| SCHEMBL28154255 | 0.80 | KDM4E (0.34) | KDM4ETDP1MMP3 | |
| SCHEMBL15955617 | 0.80 | KDM4E (0.34) | KDM4ETDP1 | |
| SCHEMBL481477 | 0.77 | ENPP2 (0.53) | KDM4ETDP1ENPP2MEN1KMT2A | |
| SCHEMBL8657492 | 0.74 | KDM4E (0.43) | KDM4ETDP1ENPP2MEN1KMT2A | |
| SCHEMBL480922 | 0.74 | CYP3A4 (0.41) | KDM4ETDP1ENPP2KMT2AMMP3 | |
| SCHEMBL8655473 | 0.74 | KDM4E (0.43) | KDM4ETDP1ENPP2MEN1KMT2A | |
| SCHEMBL18301559 | 0.74 | KDM4E (0.43) | KDM4ETDP1ENPP2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140308317-A1 | Polymeric Compounds And Methods Of Making And Using The Same | CELLCEUTIX CORPORATION (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140308317-A1 | Polymeric Compounds And Methods Of Making And Using The Same | CELLCEUTIX CORPORATION (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2014093225-A2 | POLYCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CELLCEUTIX CORPORATION (US) | 2014-06-19 | — | — | WO | disclosed |
| EP-0714893-B1 | 2-substituted benzothiazole derivatives useful in the treatment of diabetic complications | GRELAN PHARMACEUTICAL CO (JP) | 1998-10-21 | — | — | EP | disclosed |
| US-5700819-A | ALDOSE REDUCTASE ENZYME INHIBITOR | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1997-12-23 | — | — | US | disclosed |
| EP-0714893-A1 | 2-substituted benzothiazole derivatives useful in the treatment of diabetic complications | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140308317-A1 | Polymeric Compounds And Methods Of Making And Using The Same | ALG1, CD44, MUC1 | KDM4E 4424/4885TDP1 3844/4885ENPP2 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.